Transcriptomics Market Report 2026

The transcriptomics market size has grown strongly in recent years. It will grow from $7.04 billion in 2025 to $7.61 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to advancements in sequencing technologies, declining cost of high-throughput analysis, expansion of academic genomics research, availability of standardized transcriptomic workflows, growth in life sciences funding.

The transcriptomics market size is expected to see strong growth in the next few years. It will grow to $10.3 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing integration of ai-driven data analysis, rising demand for personalized therapeutics, expansion of clinical transcriptomics applications, growing investments in omics research infrastructure, increasing pharmaceutical adoption of transcriptomic profiling. Major trends in the forecast period include increasing adoption of rna sequencing technologies, growing use of single-cell transcriptomics, expansion of bioinformatics and data analytics platforms, rising demand for biomarker discovery applications, enhanced focus on precision medicine.

The growing adoption of personalized medicine is expected to drive the growth of the transcriptomics market in the coming years. Personalized medicine is a medical approach that tailors treatment based on an individual’s genetic profile, lifestyle, and environment. Its adoption is increasing due to advances in genetic sequencing, which allow treatments to be customized for better effectiveness. Transcriptomics reveals individual gene expression profiles, guiding personalized therapies according to a patient’s unique biology. This approach enhances therapeutic effectiveness, reduces side effects, and enables early disease diagnosis. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based healthcare organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the rising adoption of personalized medicine is supporting the growth of the transcriptomics market.

Leading companies in the transcriptomics market are focusing on advanced technologies, such as single-cell spatial panels, to gain deeper insights into cellular functions and disease mechanisms. Single-cell spatial panels analyze gene expression at the level of individual cells while preserving each cell’s position within the tissue. They combine single-cell transcriptomics with spatial information, providing insights into both cellular activity and tissue architecture. For example, in February 2024, NanoString Technologies, a US-based biotechnology company, launched the CosMx 6,000 plex RNA Assay, a spatial molecular imaging assay. This launch introduced the industry’s first single-cell spatial panel capable of measuring over 6,000 RNA targets across nearly all human biological pathways. Designed for use with the CosMx Spatial Molecular Imager (SMI), this technology enables researchers to profile genes at single-cell and subcellular resolution with high accuracy and advanced cell segmentation.

In July 2024, Illumina, Inc., a US-based provider of DNA sequencing and array-based technologies, acquired Fluent BioSciences Inc. for an undisclosed amount. This acquisition aims to enhance Illumina’s multiomics capabilities by integrating Fluent’s scalable single-cell technology, which eliminates the need for complex and costly instrumentation, lowering barriers for researchers and enabling faster, more economical, and comprehensive discoveries in genomics and cell biology. Fluent BioSciences Inc. is a US-based company specializing in single-cell analysis technology, a key method in transcriptomics that allows researchers to profile gene expression at the individual cell level.

Major companies operating in the transcriptomics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Becton Dickinson and Company, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Takara Bio Inc., 10x Genomics Inc., Oxford Nanopore Technologies plc, Genewiz Inc., Pacific Biosciences of California Inc., NanoString Technologies Inc., Singleron Biotechnologies, SCIEX, CD Genomics Inc., Parse Biosciences Inc., Lexogen GmbH, LC Sciences LLC, Arraystar Inc.

North America was the largest region in the transcriptomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transcriptomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the transcriptomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the transcriptomics market by increasing costs of imported sequencing instruments, reagents, consumables, laboratory automation systems, and data processing hardware. Research institutions and pharmaceutical companies in North America and Europe are most affected due to reliance on imported high-end equipment, while Asia-Pacific faces increased costs for technology-intensive research expansion. These tariffs elevate project costs and may delay large-scale studies. However, they are also encouraging domestic manufacturing of laboratory instruments, regional reagent production, and localized development of bioinformatics software solutions.

The transcriptomics market research report is one of a series of new reports that provides transcriptomics market statistics, including transcriptomics industry global market size, regional shares, competitors with a transcriptomics market share, detailed transcriptomics market segments, market trends and opportunities, and any further data you may need to thrive in the transcriptomics industry. This transcriptomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Transcriptomics is the study of all ribonucleic acid (RNA) transcripts generated by the genome within a specific cell, tissue, or condition. It provides insights into gene expression patterns and regulatory mechanisms, showing how these change in response to diseases or environmental factors. This field offers a comprehensive understanding of cellular functions and disease pathways and is essential for biomarker discovery, identifying therapeutic targets, and advancing personalized medicine.

The main categories of transcriptomics include instruments, consumables, software, and services. Instruments are critical tools that enable accurate analysis of gene expression through high-throughput sequencing, amplification, and RNA detection. The field employs technologies such as microarrays, real-time quantitative polymerase chain reaction (qPCR), and sequencing methods for applications including diagnostics, disease profiling, drug discovery, and more. Transcriptomics tools and services are used by a variety of end users, including academic and research institutions, pharmaceutical companies, biotechnology firms, and others.

The transcriptomics market consists of revenues earned by entities by providing services such as voice gene expression analysis, ribonucleic acid sequencing, bioinformatics solutions, and data interpretation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The transcriptomics market also includes sales of RNA extraction kits, library preparation kits, and cDNA synthesis kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.